Citation: | SUN Dongrui, GU Xiao, YANG Jin, LI Cuirong. Diagnosis and treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion[J]. Journal of Clinical Medicine in Practice, 2021, 25(8): 34-38. DOI: 10.7619/jcmp.20200991 |
[1] |
张智宇, 柳玉华, 赵红伟, 等. Xp11. 2易位/TFE3基因融合相关性肾癌1例报告并文献复习[J]. 泌尿外科杂志: 电子版, 2017, 9(1): 61-63. doi: 10.3969/j.issn.1674-7410.2017.01.019
|
[2] |
KLATTE T, STREUBEL B, WRBA F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11. 2 translocation: incidence, characteristics, and prognosis[J]. Am J Clin Pathol, 2012, 137(5): 761-768. doi: 10.1309/AJCPQ6LLFMC4OXGC
|
[3] |
ISHIKAWA N, NAGASE M, TAKAMI S, et al. Xp11. 2 translocation renal cell carcinoma with SFPQ/PSF-TFE3 fusion gene: a case report with unusual histopathologic findings[J]. Pathol Res Pract, 2019, 215(9): 152479-152479. doi: 10.1016/j.prp.2019.152479
|
[4] |
MEYER P N, CLARK J I, FLANIGAN R C, et al. Xp11. 2 translocation renal cell carcinoma with very aggressive course in five adults[J]. Am J Clin Pathol, 2007, 128(1): 70-79. doi: 10.1309/LR5G1VMXPY3G0CUK
|
[5] |
马文亮, 刘宁, 庄文渊, 等. Xp11. 2易位/TFE3基因融合相关性肾癌单中心临床分析[J]. 中华医学杂志, 2018, 98(38): 3068-3073. doi: 10.3760/cma.j.issn.0376-2491.2018.38.005
|
[6] |
陈伟, 史玉振, 王亚婷, 等. XP11. 2易位/TFE3基因融合相关性肾癌的MSCT表现及病理特征分析[J]. 临床放射学杂志, 2019, 38(7): 1278-1281. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS201907029.htm
|
[7] |
WOO S, KIM S Y, LEE M S, et al. MDCT findings of renal cell carcinoma associated with Xp11. 2 translocation and TFE3 gene fusion and papillary renal cell carcinoma[J]. AJR Am J Roentgenol, 2015, 204(3): 542-549. doi: 10.2214/AJR.14.12950
|
[8] |
HE J, GAN W D, LIU S, et al. Dynamic computed tomographic features of adult renal cell carcinoma associated with Xp11. 2 translocation/TFE3 gene fusions: comparison with clear cell renal cell carcinoma[J]. J Comput Assist Tomogr, 2015, 39(5): 730-736. doi: 10.1097/RCT.0000000000000263
|
[9] |
CHEN X, YANG Y, GAN W, et al. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11. 2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article[J]. Medicine: Baltimore, 2015, 94(19): e873. doi: 10.1097/MD.0000000000000873
|
[10] |
张旭婷, 任基伟, 靳宏星, 等. Xp11. 2易位/TFE3基因融合相关性肾癌的影像诊断与鉴别诊断[J]. 医学影像学杂志, 2019, 29(6): 997-1001. https://www.cnki.com.cn/Article/CJFDTOTAL-XYXZ201906030.htm
|
[11] |
ARGANI P, ANTONESCU C R, COUTURIER J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X; 1)(p11. 2; q21)[J]. Am J Surg Pathol, 2002, 26(12): 1553-1566. doi: 10.1097/00000478-200212000-00003
|
[12] |
ARGANI P, LAL P, HUTCHINSON B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay[J]. Am J Surg Pathol, 2003, 27(6): 750-761. doi: 10.1097/00000478-200306000-00005
|
[13] |
简武, 甘怀勇, 承泽农, 等. Xp11. 2易位/TFE3基因融合相关性肾细胞癌10例的临床病理特征[J]. 临床与病理杂志, 2019, 39(3): 503-508. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB201903007.htm
|
[14] |
苏明昌, 付伟金. Xp11. 2易位/TFE3基因融合相关性肾癌研究进展[J]. 泌尿外科杂志: 电子版, 2018, 10(3): 1-4. doi: 10.3969/j.issn.1674-7410.2018.03.001
|
[15] |
陆奇, 傅斌, 刘伟鹏, 等. Xp11. 2易位/TFE3基因融合相关性肾癌1例报告及文献复习[J]. 临床泌尿外科杂志, 2016, 31(10): 929-931. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201610019.htm
|
[16] |
SUDOUR-BONNANGE H, LEROY X, CHAUVET M P, et al. Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager[J]. Pediatr Blood Cancer, 2014, 61(9): 1698-1700. doi: 10.1002/pbc.25015
|